Enhancement of α-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro -: Implications for vaccine design

被引:109
作者
Joyce, JG [1 ]
Hurni, WM
Bogusky, MJ
Garsky, VM
Liang, XP
Citron, MP
Danzeisen, RC
Miller, MD
Shiver, JW
Keller, PM
机构
[1] Merck Res Labs, Dept Virus & Cell Biol, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA
[3] Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA
关键词
D O I
10.1074/jbc.M205862200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The synthetic peptide DP178, derived from the carboxyl-terminal heptad repeat region of human immunodeficiency virus type 1 GP41 protein is a potent inhibitor of viral-mediated fusion and contains the sequence ELDKWA, which constitutes the recognition epitope for the broadly neutralizing human monoclonal antibody 2F5. Efforts at eliciting a 2F5-like immune response by immunization with peptides or fusion proteins containing this sequence have not met with success, possibly because of incorrect structural presentation of the epitope. Although the structure of the carboxyl-terminal heptad repeat on the virion is not known, several recent reports have suggested a propensity for a-helical conformation. We have examined DP178 in the context of a model for optimized a-helices and show that the native sequence conforms poorly to the model. Solution conformation of DP178 was studied by circular dichroism and NMR spectroscopy and found to be predominantly random, consistent with previous reports. NMR mapping was used to show that the low percentage of a-helix present was localized to residues Glu(662) through Asn(671), a region encompassing the 2F5 epitope. Using NH2-terminal extensions derived from either GP41 or the yeast GCN4 leucine zipper dimerization domain, we designed peptide analogs in which the average helicity is significantly increased compared with DP178 and show that these peptides exhibit both a modest increase in affinity for 2F5 using a novel competitive solution-based binding assay and an increased ability to inhibit viral entry in a single-cycle infectivity model. Selected peptides were conjugated to carrier protein and used for guinea pig immunizations. High peptide-specific titers were achieved using these immunogens, but the resulting sera were incapable of viral neutralization. We discuss these findings in terms of structural and immunological considerations as to the utility of a 2F5-like response.
引用
收藏
页码:45811 / 45820
页数:10
相关论文
共 60 条
[1]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[2]   MLEV-17-BASED TWO-DIMENSIONAL HOMONUCLEAR MAGNETIZATION TRANSFER SPECTROSCOPY [J].
BAX, A ;
DAVIS, DG .
JOURNAL OF MAGNETIC RESONANCE, 1985, 65 (02) :355-360
[3]   PREDICTING COILED COILS BY USE SF PAIRWISE RESIDUE CORRELATIONS [J].
BERGER, B ;
WILSON, DB ;
WOLF, E ;
TONCHEV, T ;
MILLA, M ;
KIM, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) :8259-8263
[4]   STRUCTURE DETERMINATION OF A TETRASACCHARIDE - TRANSIENT NUCLEAR OVERHAUSER EFFECTS IN THE ROTATING FRAME [J].
BOTHNERBY, AA ;
STEPHENS, RL ;
LEE, JM ;
WARREN, CD ;
JEANLOZ, RW .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1984, 106 (03) :811-813
[5]   COHERENCE TRANSFER BY ISOTROPIC MIXING - APPLICATION TO PROTON CORRELATION SPECTROSCOPY [J].
BRAUNSCHWEILER, L ;
ERNST, RR .
JOURNAL OF MAGNETIC RESONANCE, 1983, 53 (03) :521-528
[6]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[7]   Core structure of gp41 from the HIV envelope glycoprotein [J].
Chan, DC ;
Fass, D ;
Berger, JM ;
Kim, PS .
CELL, 1997, 89 (02) :263-273
[8]   Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target [J].
Chan, DC ;
Chutkowski, CT ;
Kim, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15613-15617
[9]   HIV entry and its inhibition [J].
Chan, DC ;
Kim, PS .
CELL, 1998, 93 (05) :681-684
[10]   Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein [J].
Coëffier, E ;
Clément, JM ;
Cussac, V ;
Khodaei-Boorane, N ;
Jehanno, M ;
Rojas, M ;
Dridi, A ;
Latour, M ;
El Habib, R ;
Barré-Sinoussi, F ;
Hofnung, M ;
Leclerc, C .
VACCINE, 2000, 19 (7-8) :684-693